tiprankstipranks
Trending News
More News >
Sagami Rubber Industries Co., Ltd. (JP:5194)
:5194
Japanese Market

Sagami Rubber Industries Co., Ltd. (5194) AI Stock Analysis

Compare
0 Followers

Top Page

JP:5194

Sagami Rubber Industries Co., Ltd.

(5194)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
¥685.00
▼(-6.68% Downside)
Action:ReiteratedDate:11/18/25
The overall stock score of 52 reflects a stable financial structure but is weighed down by bearish technical indicators and poor valuation metrics. The company's challenges in revenue growth and profitability, combined with weak market sentiment, contribute to the lower score.
Positive Factors
Balance Sheet Strength
A controlled leverage profile and a strong equity ratio provide durable financial flexibility. This supports capital expenditure, working-capital needs and resilience through demand cycles, reducing refinancing risk and enabling strategic investments over the next 2–6 months.
Operating Cash Generation
Consistent conversion of earnings into cash and improved free cash flow underpin the company's ability to fund operations, payoff obligations, and maintain shareholder returns without relying on external financing, strengthening long-term liquidity and investment capacity.
Diversified Business Model
A dual-channel model (branded retail and OEM contract manufacturing) provides structural revenue diversification. This reduces single-customer concentration risk, smooths volumes across channels, and allows margin mix management, supporting durable revenue resilience.
Negative Factors
Revenue Decline
Sustained revenue contraction and falling gross margins indicate structural demand or pricing pressure. Over months this erodes operating leverage, limits reinvestment capacity, and risks market share loss if product or distribution issues are not addressed.
Negative EBIT Margin
A negative EBIT margin signals persistent cost or efficiency problems that impair core profitability. Without operational improvement, negative operating earnings constrain strategic flexibility, capital allocation and the ability to sustain investments in product or distribution.
Volatile Profitability and FCF Growth
Inconsistent free cash flow and volatile returns on equity increase execution risk for budgeting, dividends and capex. This variability complicates multi-quarter planning and weakens the reliability of cash available for strategic initiatives or deleveraging.

Sagami Rubber Industries Co., Ltd. (5194) vs. iShares MSCI Japan ETF (EWJ)

Sagami Rubber Industries Co., Ltd. Business Overview & Revenue Model

Company DescriptionSagami Rubber Industries Co., Ltd. primarily manufactures and supplies condoms. The company offers polyurethane and latex condoms, external catheters, and probe covers; plastic films; and healthcare products and services. It sells its products in Japan, France, Switzerland, Italy, Portugal, Spain, Finland, Norway, Sweden, Korea, Vietnam, Mexico, and the United States. The company was founded in 1934 and is headquartered in Atsugi, Japan.
How the Company Makes MoneySagami Rubber Industries generates revenue primarily through the sale of its condom products, which are distributed both domestically in Japan and internationally. The company benefits from a strong brand reputation and a loyal customer base, which helps drive sales in a competitive market. Key revenue streams include retail sales through pharmacies, convenience stores, and supermarkets, as well as online sales channels. Additionally, Sagami has entered into partnerships with various health organizations and distributors, expanding its market reach and enhancing its product visibility. The company also invests in research and development to innovate new products, ensuring it stays ahead of industry trends and consumer preferences, further contributing to its earnings.

Sagami Rubber Industries Co., Ltd. Financial Statement Overview

Summary
Sagami Rubber Industries Co., Ltd. shows a stable financial structure with a strong balance sheet and efficient cash management. However, challenges in revenue growth and operational profitability, as indicated by the income statement, need to be addressed to improve overall financial health.
Income Statement
65
Positive
The income statement shows a mixed performance with declining total revenue over the years. Gross profit margin has been shrinking, indicating pressure on cost management or pricing power. The net profit margin has seen significant fluctuation, with recent recovery in profitability. However, the EBIT margin is negative for the latest period, suggesting challenges in operational efficiency or increased expenses. Revenue growth has been negative, indicating a contraction in sales.
Balance Sheet
70
Positive
The balance sheet reflects a stable financial structure with a reasonable debt-to-equity ratio, demonstrating controlled leverage. The equity ratio indicates a strong position, showing that a significant portion of assets is financed by equity. However, the return on equity has been volatile, suggesting inconsistent profitability. Overall, the company maintains solid asset management but needs to improve its return on equity.
Cash Flow
75
Positive
Cash flow analysis depicts positive trends with sustained operating cash flow generation and improved free cash flow over the years. The operating cash flow to net income ratio is robust, indicating efficient conversion of income into cash. Free cash flow to net income ratio highlights strong cash generation relative to earnings. However, free cash flow growth has been inconsistent, reflecting potential volatility in cash management.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue6.02B5.69B6.11B5.98B5.41B5.59B
Gross Profit1.61B1.47B1.83B1.89B2.24B2.43B
EBITDA1.23B1.47B1.14B1.75B2.00B1.46B
Net Income175.89M392.54M40.96M673.52M1.10B598.05M
Balance Sheet
Total Assets18.28B18.64B17.72B18.15B17.04B15.72B
Cash, Cash Equivalents and Short-Term Investments2.05B1.93B1.19B1.85B1.53B1.47B
Total Debt5.59B5.66B5.74B6.41B6.50B6.46B
Total Liabilities7.51B7.52B7.61B8.20B8.12B8.15B
Stockholders Equity10.51B10.84B9.84B9.66B8.66B7.33B
Cash Flow
Free Cash Flow0.00693.67M241.52M711.94M230.31M-753.05M
Operating Cash Flow0.00790.28M373.60M898.87M905.32M1.41B
Investing Cash Flow0.00438.49M-133.05M-184.86M-675.76M-2.16B
Financing Cash Flow0.00-503.15M-906.58M-422.13M-189.90M671.23M

Sagami Rubber Industries Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price734.00
Price Trends
50DMA
700.36
Negative
100DMA
766.14
Negative
200DMA
842.90
Negative
Market Momentum
MACD
-7.10
Negative
RSI
44.77
Neutral
STOCH
70.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5194, the sentiment is Neutral. The current price of 734 is above the 20-day moving average (MA) of 673.65, above the 50-day MA of 700.36, and below the 200-day MA of 842.90, indicating a neutral trend. The MACD of -7.10 indicates Negative momentum. The RSI at 44.77 is Neutral, neither overbought nor oversold. The STOCH value of 70.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:5194.

Sagami Rubber Industries Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥1.89T28.6710.79%3.47%-1.56%-1.15%
76
Outperform
¥508.74B18.439.77%1.73%2.18%60.81%
71
Outperform
¥568.79B16.0113.22%1.53%18.35%31.87%
70
Outperform
¥3.05T25.6411.70%2.41%4.62%47.68%
65
Neutral
¥431.11B118.545.37%1.95%-3.33%13.76%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
52
Neutral
¥7.36B168.931.37%-2.67%-143.38%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:5194
Sagami Rubber Industries Co., Ltd.
678.00
-244.87
-26.53%
JP:4452
Kao
6,744.00
378.89
5.95%
JP:4967
Kobayashi Pharmaceutical Co
5,813.00
352.93
6.46%
JP:4912
Lion
1,874.50
160.39
9.36%
JP:4527
Rohto Pharmaceutical Co
2,450.00
312.05
14.60%
JP:8113
Unicharm
1,035.00
-91.78
-8.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 18, 2025